此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

2017年10月9日 更新者:GlaxoSmithKline

A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids

The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.

研究概览

研究类型

介入性

注册 (实际的)

348

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Dnipropetrovsk、乌克兰、49074
        • GSK Investigational Site
      • Dnipropetrovsk、乌克兰、49027
        • GSK Investigational Site
      • Donetsk、乌克兰、83099
        • GSK Investigational Site
      • Ivano-Frankivsk、乌克兰、76018
        • GSK Investigational Site
      • Kharkiv、乌克兰、61124
        • GSK Investigational Site
      • Kharkiv、乌克兰、61037
        • GSK Investigational Site
      • Kyiv、乌克兰、03680
        • GSK Investigational Site
      • Simferopol、乌克兰、95043
        • GSK Investigational Site
      • Yalta、乌克兰、98603
        • GSK Investigational Site
    • Bayern
      • Gauting、Bayern、德国、82131
        • GSK Investigational Site
    • Hessen
      • Frankfurt、Hessen、德国、60596
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Mainz、Rheinland-Pfalz、德国、55131
        • GSK Investigational Site
    • Schleswig-Holstein
      • Grosshansdorf、Schleswig-Holstein、德国、22927
        • GSK Investigational Site
      • Chrzanow、波兰、32-500
        • GSK Investigational Site
      • Krakow、波兰、31-024
        • GSK Investigational Site
      • Krakow、波兰、31-455
        • GSK Investigational Site
      • Krakow、波兰、30-901
        • GSK Investigational Site
      • Lublin、波兰、20-552
        • GSK Investigational Site
      • Lima、秘鲁、Lima 27
        • GSK Investigational Site
    • Lima
      • Callao、Lima、秘鲁、Callao 2
        • GSK Investigational Site
      • Lima 27、Lima、秘鲁、Lima 27
        • GSK Investigational Site
      • San Isidro、Lima、秘鲁、Lima 27
        • GSK Investigational Site
      • San Miguel、Lima、秘鲁、Lima 32
        • GSK Investigational Site
    • California
      • Huntington Beach、California、美国、92647
        • GSK Investigational Site
    • Florida
      • Orlando、Florida、美国、32822
        • GSK Investigational Site
      • Tallahassee、Florida、美国、32308
        • GSK Investigational Site
    • Georgia
      • Lawrenceville、Georgia、美国、30046
        • GSK Investigational Site
    • New Jersey
      • Skillman、New Jersey、美国、08558
        • GSK Investigational Site
    • North Carolina
      • Raleigh、North Carolina、美国、27607
        • GSK Investigational Site
    • Ohio
      • Cincinnati、Ohio、美国、45231
        • GSK Investigational Site
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73103
        • GSK Investigational Site
    • South Carolina
      • Chester、South Carolina、美国、29706
        • GSK Investigational Site
      • Clinton、South Carolina、美国、29325
        • GSK Investigational Site
      • Orangeburg、South Carolina、美国、29118
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Outpatient at least 12 years of age
  • Both genders; females of childbearing potential must be willing to use birth control method
  • Clinical diagnosis of asthma for ≥12 weeks
  • Best pre-bronchodilator FEV1 of 40%-90% predicted
  • Reversibility of FEV1 of at least 12% and 200mls
  • Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit
  • Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits

Exclusion Criteria:

  • History of life-threatening asthma
  • Respiratory infection within last 4 weeks leading to change in asthma management
  • Asthma exacerbation within last 3 months
  • Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
  • Allergies to study drugs, study drugs' excipients, or medications related to study drugs
  • Taking another investigational medication or medication prohibited for use during the study.
  • Previous participation in a vilanterol (GW642444) study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Vilanterol
Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Placebo inhalation powder inhaled orally twice daily for 12 weeks
有源比较器:Salmeterol
Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
安慰剂比较:Placebo
Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
Placebo inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12
大体时间:Baseline and Week 12
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12. The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
Baseline and Week 12

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
大体时间:Baseline and Weeks 1-12
The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Baseline and Weeks 1-12
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
大体时间:Baseline and Weeks 1-12
Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed. The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization). Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Baseline and Weeks 1-12
Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points
大体时间:Baseline and Week 12
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second. The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12). The Baseline value was the Day 1 pre-dose FEV1 measurement. Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment. Analysis was performed separately for each planned time point.
Baseline and Week 12
Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
大体时间:Baseline and Weeks 1-12
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization. Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Baseline and Weeks 1-12
Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period
大体时间:Baseline and Weeks 1-12
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated. Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug. The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization. Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline. Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
Baseline and Weeks 1-12
Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)
大体时间:Day 1 and Week 12
The number of participants with a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a >=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points. Participants who did not achieve a >=12% and >=200 mL increase from Baseline in FEV1 over this time period were considered censored.
Day 1 and Week 12
Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12
大体时间:Week 4 and Week 12
At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.
Week 4 and Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年9月1日

初级完成 (实际的)

2011年8月1日

研究完成 (实际的)

2011年8月26日

研究注册日期

首次提交

2010年7月15日

首先提交符合 QC 标准的

2010年8月12日

首次发布 (估计)

2010年8月13日

研究记录更新

最后更新发布 (实际的)

2017年11月8日

上次提交的符合 QC 标准的更新

2017年10月9日

最后验证

2017年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

研究数据/文件

  1. 临床研究报告
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  2. 带注释的病例报告表
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  3. 知情同意书
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  4. 统计分析计划
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  5. 个人参与者数据集
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  6. 研究协议
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register
  7. 数据集规范
    信息标识符:112060
    信息评论:For additional information about this study please refer to the GSK Clinical Study Register

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅